Skip to content
Parakho

Orchid Pharma Ltd

NSE ORCHPHARMABSE 524372orchidpharma.com

Q1 FY27, unaudited

Revenue
₹304.17 Cr
Profit after tax
₹3.22 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations304.17+75.89%1,232.78
Other income1.83−84.03%36.42
Total income306.00+65.96%1,269.20
Employee benefit expense28.04+29.73%117.65
Finance costs2.23−31.54%8.98
Depreciation & amortisation10.95+26.52%43.25
Total expenses303.35+77.75%1,251.44
Profit before tax2.65−80.68%10.43
Tax expense0.07—-0.19
Profit after tax3.22−78.38%9.96
Total comprehensive income3.23−78.10%11.28
Earnings per share
Earnings per share, basic₹0.54₹1.66
Earnings per share, diluted₹0.54₹1.66

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Orchid Pharma reported Q4 FY26 standalone revenue of approximately Rs 238 crore, broadly stable versus Rs 237 crore in Q4 FY25, while full-year FY26 revenue fell to Rs 811 crore from Rs 922 crore in FY25 amid industry-wide pricing pressure in Cephalosporins. Management said gross margins recovered in Q4 after inventory revaluation losses hurt earlier quarters, and discussed progress on the 7ACA project, Exblifep commercialization, Cefiderocol facility, and the pending merger with Dhanuka Laboratories. Management also outlined plans to build fill-finish and formulation capabilities to target the U.S. sterile Cephalosporin market.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 39 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 24 Aug 2026.